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Purpose: Northern Thailand is a tuberculosis (TB) endemic area with a high TB death rate. 
We aimed to establish the time of highest death risk during TB treatment, and to identify the 
risk factors taking place during that period of high risk.
Patients and methods: We explored the TB surveillance data of the Chiang Rai province, 
Northern Thailand, retrospectively for 12 years. A total of 19,174 TB patients (including 5,009 
deaths) were investigated from 1997 to 2008, and the proportion of deaths in each month of TB 
treatment was compared. Furthermore, multiple logistic regression analysis was performed to 
identify the characteristics of patients who died in the first month of TB treatment. A total of 
5,626 TB patients from 2005 to 2008 were included in this regression analysis.
Result: The numbers of deaths in the first month of TB treatment were 38%, 39%, and 46% in 
the years 1997–2000, 2001–2004, and 2005–2008, respectively. The first month of TB treatment 
is the time of the maximum number of deaths. Moreover, advancing age, HIV infection, and 
being a Thai citizen were significant factors contributing to these earlier deaths in the course 
of TB treatment.
Conclusion: Our findings have pointed to the specific time period and patients at higher risk 
for TB death. These findings would be useful for prioritizing interventions in order to diminish 
TB-related deaths globally. Studies based on these findings are necessary for the introduction 
of newer intervention strategies.
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Introduction
Tuberculosis (TB) is still a worldwide deadly threat despite global and national control 
  programs. Every year there are two million TB-related deaths globally.1 The global TB 
mortality rate was 29/100,000 in 1990 and increased to peak at 32/100,000 in 2000 
before decreasing to 27/100,000 in 2007.2 After a decades-long battle against TB, the 
World Health   Organization (WHO) has set the goal to reduce TB mortality below 
15 per 100,000 by 2015.
TB mortality rate is different in developing and developed countries. A Centers for 
Disease Control and Prevention surveillance report in 2008 showed that TB mortality in 
the United States was 0.2 per 100,000.3 In contrast, Thailand, which was ranked 18th of 
the top 22 highest TB-burdened countries, had a mortality rate of 21/100,000 in 2007.4 
Furthermore, even with the low level of mortality, the proportion of pulmonary TB patients 
who died during treatment was reported to be highest in the WHO European region.2,5 
The disease is still the cause of death for large numbers of people across the world.
In recent years, Thailand could not achieve the WHO target treatment success rate. 
One of the reasons for this is the high proportion of TB death on treatment: 11% in 2001 International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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and 9% in 2007, which were the highest proportions in the 
WHO Southeast Asian region. These figures were very simi-
lar to the proportion of TB patients’ deaths (8%) reported by 
the European region, which was the highest among all WHO 
regions in 2007.5 Chiang Rai province, the study site of the 
current study, is a TB and HIV endemic area. It has a higher 
TB case fatality rate (17.1%) than its neighboring provinces 
in Northern Thailand.6 Previous literature has stated that 
living in Chiang Rai province itself is a risk factor of death 
among TB patients (adjusted relative risk 2.7).7
TB is a chronic communicable disease that is curable. 
Moreover, TB death is preventable. To aid prevention, it is 
necessary to specify the time, place, and persons at higher risk of 
death. Identifying the time when most TB deaths occur during 
the course of treatment is necessary.   Characteristics of patients 
who died of TB during that high-risk period should be observed 
to specify social and clinical risk groups of TB death.
We aimed to find out the time of highest on-treatment 
death along the timeline of TB treatment. Furthermore, we 
tried to identify the characteristics of TB patients who died 
during that high-risk period.
Material and methods
Data collection and source
TB surveillance data were used for the study. The study was 
approved by Chiang Rai Ethical Committee and Chiang Rai 
Provincial Health Office, Thailand. TB surveillance data 
covered 17 hospitals in Chiang Rai province.
study population
The study population comprised TB patients selected based 
on the following criteria. These criteria were applied for both 
parts of the analysis.
Inclusion criteria
1.  All TB cases treated and reported in Chiang Rai province, 
including new cases, relapse, treatment after failure, 
treatment after default, and others according to WHO 
criteria.
2.  Pulmonary as well as extrapulmonary tuberculosis.
exclusion criteria
1.  Defaulted TB cases.
2.  Transfer-in cases from other areas and transfer-out cases 
during treatment.
3.  Patients less than 16 years of age.
The study contained two parts. In the first part of the 
study, TB surveillance data of the past 12 years were 
  examined. All 5009 deaths among 19,174 TB patients from 
1997 to 2008 were retrospectively studied.
Secondly, to analyze the factors associated with patients 
who died during the period of highest death, prospectively 
collected data were used. A total of 5,626 TB patients from 
2005 to 2008 were included in the second part of the analysis. 
Populations in the first and second part of the analysis had the 
same criteria for inclusion and exclusion.   Hypothesis-driven 
data collection was started in 2005 beyond the scope of 
routine surveillance. It was made successful because of the 
Thailand TB Active Surveillance Network (TB-Net). TB-Net 
was a collaboration of the Ministry of Public Health, Thai-
land, Bangkok Metropolitan Administration, the Research 
Institute of Tuberculosis, Japan, and the U.S. Centers for 
Disease Control and Prevention in five provinces of Thailand, 
including Chiang Rai. This analysis used the data collected 
by the RIT in Chiang Rai province.
TB treatment
TB patients in Chiang Rai province were treated according to 
National TB Program treatment guidelines. Choice of TB 
treatment regimen was based on the criteria of new case, 
retreatment, and drug resistance regimen according to the 
treatment category in the WHO guidelines.8
Death
Death from any cause during TB treatment was listed as 
on-treatment TB death according to the WHO TB treatment 
outcome definition.8 Death during TB treatment was con-
firmed by using hospital records and the death registry in 
the online national vital status database.
Laboratory tests
Microscopic examination of sputum samples for acid-fast bacilli 
by Ziehl–Neelsen stain was carried out in the   mycobacterial lab-
oratory of each hospital in Chiang Rai province.   Bacteriological 
diagnosis of tuberculosis culture was done at the mycobacterial 
laboratory of the Chiang Rai provincial hospital. Throughout 
the study period, solid culture via Ogawa medium was used. 
After October 2005, automated liquid culture system BactecTM 
Mycobacterial Growth Indicator Tube (MGIT 960TM) was used 
for TB culture. Drug susceptibility tests (DSTs) were carried out 
at the National TB Reference Laboratory, Bangkok, Thailand, 
by using the proportion method with a Lowenstein–Jensen 
medium before 2005. After 2005, identification and DSTs 
for isoniazid, rifampicin, ethambutol, and streptomycin were 
performed at the National TB Reference Laboratory using 
MGIT. Voluntary   counseling and testing of HIV infection was International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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offered to every TB patient. Consented cases were tested for 
HIV antibody.
statistical analysis
Stata Version 11 was used to analyze the data. Of 5009 total 
deaths from 1997 to 2008, the number and proportion of 
deaths in each month of TB treatment were analyzed descrip-
tively and shown graphically for every 4-year interval for 
1997–2000, 2001–2004, and 2005–2008 (Figures 1A–1C).
A total of 5,009 deaths occurred among 19,174 reported 
TB patients within 12 years. The events of death were ana-
lyzed against the timeline of TB treatment using smooth 
hazard risk estimation. The probability of death in the time-
line of TB treatment was extrapolated by Kernel smoothed 
hazard rates estimation curve (Figure 2).
Backward multilogistic regression analysis was per-
formed to identify factors associated with the TB patients 
who died within the first month. Factors that contributed 
to 534 TB patients’ deaths in the first month of treatment 
were investigated and compared with 5,092 survivors. Mul-
tiple logistic regression was restricted to variables with a   
P value less than 0.1 in bivariate analysis. Gender, age, race, 
marital status, education, occupation, BCG scar, patient type 
based on treatment regimen, and HIV status were included in 
multilogistic regression. A P value less than 0.05 was con-
sidered statistically significant, with a 95 percent confidence 
interval (CI) to determine adjusted odds ratio (aOR).
Results
First part of the analysis
Our observation showed that the largest number of TB 
patients died in the first month of TB treatment. Death rates 
in the first month were 38% of all TB deaths in 1997–2000, 
39% of all TB death in 2001–2004, and 46% of all TB death 
in 2005–2008 (Figures 1A, 1B, and 1C). The largest propor-
tion of TB patients died in the first month of TB treatment 
in a constant pattern for 12 years.
The result of time-event analysis by Kernel smoothed 
hazard rates estimation curve revealed higher probability 
of TB death in the first month (Figure 2). The trend of 
TB deaths can be seen to decline over the timeline of TB 
treatment.
second part of the analysis
Analysis of factors associated with TB deaths in the first 
month included 5626 TB patients. The basic characteristics 
of patients are shown in Table 1. The proportion of male 
patients was higher than female patients. More than 85% 
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Figure 1 A) Deaths of TB patients in each month of TB treatment in chiang rai, 
Thailand (1997–2000). B) Deaths of TB patients in each month of TB treatment in 
chiang rai, Thailand (2001–2004). C) Deaths of TB patients in each month of TB 
treatment in chiang rai, Thailand (2005–2008).
0
100
200
300
400
500
600
700
Death number
Proportion
N
u
m
b
e
r
 
o
f
 
T
B
 
p
a
t
i
e
n
t
s
 
d
i
e
d
P
r
o
p
o
r
t
i
o
n
 
o
f
 
T
B
 
p
a
t
i
e
n
t
s
 
d
i
e
d
1234567891 01 11 2
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
Time on TB treatment (months)
B
600
500
400
300
200
100
0
12345679 8
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
10 11 12
Death number
Proportion
P
r
o
p
o
r
t
i
o
n
 
o
f
 
T
B
 
p
a
t
i
e
n
t
s
 
d
i
e
d
N
u
m
b
e
r
 
o
f
 
T
B
 
p
a
t
i
e
n
t
s
 
d
i
e
d
Time on TB treatment (months)
C
of the patients were Thai, and more than a third were HIV 
infected.
The results of bivariate and multivariate analysis are 
shown in Table 2. Age group, HIV status, and being a Thai cit-
izen were significant risk factors associated with death in the 
first month of TB treatment after adjustment by multivariate International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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analysis. The risk of death in the first month of TB treatment 
was found to be higher with advancing age (Figure 3).
Adjusted odds ratio were: aOR 17.1, CI 8.54–36.73 for age 
above 65 years; aOR 8.76, CI 4.15–18.45 in age 56–65 years 
group; aOR 4.60, CI 2.22–9.54 in age 46–55 years group; 
aOR 2.53, CI 1.23–5.21 in age 36–45 years group; and aOR 
2.57, CI 1.26–5.24 in age 26–35 years group compared with 
the age 16–25 years group.
HIV-positive patients are more likely to die in the first 
month of TB treatment (aOR 3.24, CI 2.46–4.26) than 
  HIV-negative patients. Thai citizens have a higher risk of TB 
death in the first month of treatment (aOR 2.26, CI 1.28–4.00) 
than Myanmar and Lao migrants. Married patients have less 
risk for TB death in the first month (aOR 0.61, CI 0.45–0.83) 
than single patients.
Discussion
Time of highest on-treatment TB death
Death caused by TB is preventable. Management and care 
can be modified at the time of highest risk for death. Many 
researches and reports have discussed TB mortality and fac-
tors associated with TB mortality. Usually, all TB deaths are 
summarized as one of the treatment outcomes at the end of 
TB treatment. There is still a gap in the evidence needed to 
know the time of highest mortality.
Our observation of surveillance data over 12 years 
revealed that the highest proportion of TB deaths hap-
pened during the first month of TB treatment. The finding 
was persistent for more than a decade (Figures 1A–1C). 
The number of overall deaths became lower during the later 
4 years 2005–2008. During 1997–2000, there was a lack 
of antiretroviral therapy (ART) for TB–HIV co-infected 
patients in Chiang Rai. After 2000, ART was provided by 
a national program, and access to ART was expanded with 
time. This may have led to an overall decline in the death 
rate in later years of observation. Nevertheless, the propor-
tion of deaths was still the highest in the first month of TB 
treatment   (Figures 1A, 1B, and 1C).
Harries et al identified in 1997 that 40% of TB deaths 
occurred in the first month of TB treatment in Malawi.9 It was 
an interesting report, with particular observation of the time of 
highest death during TB treatment. The percentage of death 
in the first month was very similar to our observation. The 
finding was based on 1-year data from the TB registry in 1997 
from 38 hospitals in Malawi. It would be more   informative 
to see the trend of TB deaths in subsequent years, because 
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Figure 2 smoothed hazard estimation of on-treatment TB deaths in chiang rai, Thailand (1997–2008). Y-axis is showing the probability of on-treatment TB death. X-aixs 
is showing the timeline of TB treatment.
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there were many changes, such as HIV prevalence, TB control 
activity, and policy. In our report, the proportion of TB deaths 
in the course of treatment can be seen serially for 12 years.
The same author in 2001 reported 40%–45% of all TB 
deaths in the first month of TB treatment regardless of daily 
or intermittent regimens in Malawi.10 All these studies were at 
the same site, Malawi, which is a TB and HIV endemic area 
in Africa. Sub-Saharan Africa has a very high HIV prevalence 
Table 1 characteristics of TB patients included in the analysis
Characteristics Patient died  
in 1 month  
N = 534  
n (%)
Patient alive   
at 1 month  
N = 5,092  
n (%)
Gender
  Male 362 (67.8%) 3332 (65.4%)
  Female 172 (32.2%) 1760 (34.6%)
Age (years)
  Above 65 188 (35.2%) 756 (14.8%)
  56–65 77 (14.4%) 569 (11.2%)
  46–55 83 (15.5%) 950 (18.7%)
  36–45 84 (15.7%) 1214 (23.8%)
  26–35 93 (17.4%) 1153 (22.6%)
  16–25 9 (1.7%) 446 (8.8%)
  Missing  – 4 (0.1%)
  Median (range) 43 (16–104) 55 (16–95)
Race
  Thai 461 (86.3%) 3732 (73.3%)
  hill tribe 53 (9.9%) 846 (16.6%)
  non-Thaia 20 (3.7%) 514 (10.1%)
Marital status
  Married 272 (50.9%) 3105 (61%)
  Divorced 38 (7.1%) 329 (6.5%)
  Widowed 105 (19.7%) 641 (12.6%)
  single 70 (13.1%) 818 (16.1%)
  Missing 49 (9.2%) 199 (3.9%)
Education
  Uneducated 114 (21.3%) 1196 (23.5%)
  Primary or lower 193 (36.1%) 1877 (36.9%)
    secondary or higher 37 (6.9%) 735 (14.4%)
  Missing 190 (35.6%) 1284 (25.2%)
Occupation
  household work 110 (20.7%) 494 (9.9%)
  Unemployed 36 (6.7%) 284 (5.6%)
  Prisoner 9 (2.4%) 76 (1.7%)
  Business owner 16 (3%) 183 (3.6%)
  Government employee 8 (1.5%) 105 (2.1%)
  Farmer 90 (18%) 1275 (26.8%)
  casual laborer 111 (22.3%) 1816 (38.3%)
  Other 2 (0.4%) 126 (2.5%)
  Missing 152 (28.5%) 733 (14.4%)
Diabetes mellitus
  Yes 21 (3.9%) 215 (4.2%)
  no 338 (63.3%) 3884 (76.3%)
  Missing 175 (32.8%) 993 (19.5%)
Intravenous drug user
  Yes 17 (3.2%) 191 (3.8%)
  no 360 (67.4%) 3934 (77.3%)
  Missing 157 (29.4%) 967 (19%)
Prisoner
  Yes 8 (1.5%) 121 (2.4%)
  no 526 (98.5%) 4971 (97.6%)
BCG scar
  Yes 85 (15.9%) 1421 (27.9%)
  no 175 (32.8%) 2159 (42.4%)
  Missing 274 (51.3%) 1512 (29.7%)
(Continued)
Table 1 (Continued)
Characteristics Patient died  
in 1 month  
N = 534  
n (%)
Patient alive   
at 1 month  
N = 5,092  
n (%)
Cough
  no 111 (20.8%) 941 (18.5%)
  .14 days 151 (28.3%) 1973 (38.7%)
  #14 days 106 (19.9%) 1129 (22.2%)
  Missing 166 (31.1%) 1049 (20.6%)
HIV status
  Positive 190 (35.6%) 1559 (30.6%)
  Unknown 62 (11.6%) 258 (5.1%)
  negative 282 (52.8%) 3275 (64.3%)
Site of tuberculosis
  extrapulmonary TB 118 (22.1%) 1137 (22.3%)
    Pulmonary TB  
smear positive
262 (49.1%) 2450 (48.1%)
    Pulmonary TB  
smear unknown
21 (3.9%) 120 (2.4%)
    Pulmonary TB  
smear negative
133 (24.9%) 1385 (27.2%)
Chest X-ray
  cavity 53 (8.7%) 568 (9.9%)
  noncavity 287 (47%) 2753 (48.1%)
  Missing 76 (12.5%) 634 (11.1%)
Patient type
  relapse 12 (2.2%) 99 (1.9%)
  Failure 5 (0.9%) 90 (1.8%)
  TAD 17 (3.2%) 198 (3.9%)
  Other 17 (3.2%) 270 (5.3%)
  new 483 (90.4%) 4435 (87.1%)
Sputum culture
  Growth 226 (54.3%) 2314 (58.5%)
  no growth 80 (19.2%) 764 (19.3%)
  Missing 110 (26.4%) 877 (22.2%)
MDR TB
  Yes 4 (1.8%) 42 (1.8%)
  no 197 (87.2%) 1947 (84.1%)
  Missing 25 (11.1%) 325 (14%)
Drug resistance
  One or moreb 33 (14.6%) 360 (15.6%)
  none 168 (74.3%) 1629 (70.4%)
  Missing 25 (11.1%) 325 (14%)
Notes: anon-Thai means migrants from Lao and Myanmar; bresistance to at least 
one or more anti-TB drug: isoniazid, rifampicin, ethambutol, and streptomycin.
Data source: TB surveillance database collaboration between chiang rai Provincial 
Health Office, Thailand, and Research Institute of Tuberculosis, Japan.
Abbreviations:  MDr-TB,  multidrug-resistant  tuberculosis; TAD,  treatment  after 
default.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Table 2 Factors associated with TB patients who died in the first month of TB treatment in Chiang Rai, Thailand (2005–2008)
Characteristics Patient died  
n/N (%)
Bivariate OR  
(95% CI)
Adjusted  
OR (95% CI)
Gender
  Male 362/3694 (9.8%) 1.11 (0.92–1.34) 1.03 (0.84–1.26)
  Female 172/1932 (8.9%) referent referent
Age (years)
  .65 188/944 (19.9%) 12.32 (6.25–24.30)c 17.71 (8.54–36.73)c
  56–65 77/646 (11.9%) 6.71 (3.33–13.52)c 8.76 (4.15–18.45)c
  46–55 83/1033 (8%) 4.33 (2.16–8.69)c 4.60 (2.22–9.54)c
  36–45 84/1298 (6.5%) 3.43 (1.71–6.88)c 2.53 (1.23–5.21)c
  26–35 93/1246 (7.5%) 4.00 (2.00–7.99)c 2.57 (1.26–5.24)c
  16–25 9/455 (2%) referent referent
Race
  Thai 461/4193 (11%) 3.17 (2.01–5.01)c 2.26 (1.28–4.00)c
  hill tribe 53/899 (5.9%) 1.61 (0.95–2.72) 1.76 (0.94–3.30)
  non-Thaia 20/534 (3.7%) referent referent
Marital status
  Married 272/3377 (8.1%) 1.02 (0.78–1.35) 0.61 (0.45–0.83)c
  Divorced 38/367 (10.4%) 1.35 (0.89–2.04) 0.80 (0.52–1.23)
  Widowed 105/746 (14.1%) 1.91 (1.39–2.64)c 0.71 (0.49–1.02)
  single 70/888 (7.9%) referent referent
Education
  Uneducated 114/1310 (8.7%) 1.89 (1.29–2.77)c ns
  Primary or lower 193/2070 (9.3%) 2.04 (1.42–2.93)c
  secondary or higher 37/772 (4.8%) referent
Occupation
  household work 110/604 (18.2%) 3.64 (2.75–4.83)c ns
  Unemployed 36/320 (11.3%) 2.07 (1.40–3.08)c
  Prisoner 9/85 (10.6%) 1.94 (0.95–3.97)
  Business owner 16/199 (8%) 1.43 (0.83–2.47)
  Government employee 8/113 (7.1%) 1.25 (0.59–2.62)
  Farmer 90/1365 (6.6%) 1.15 (0.87–1.54)
  Other 2/128 (1.6%) 0.26 (0.06–1.06)
  casual laborer 111/1927 (5.8%) referent
Diabetes mellitus
  Yes 21/236 (8.9%) 1.12 (0.71–1.78) ns
  no 338/4222 (8%) referent
Intravenous drug users
  Yes 17/208 (8.2%) 0.97 (0.59–1.62) ns
  no 360/4294 (8.4%) referent
Prisoner
  Yes 8/129 (6.2%) 0.62 (0.30–1.29) ns
  no 526/5497 (9.6%) referent
BCG scar
  Yes 85/1506 (5.6%) 0.74 (0.56–0.96)c ns
  no 175/2334 (7.5%) referent
Cough
  no 111/1052 (10.6%) 1.26 (0.95–1.66) ns
  .14 days 151/2124 (7.1%) 0.82 (0.63–1.06)
  #14 days 106/1235 (8.6%) referent
HIV status
  Positive 190/1749 (10.9%) 1.42 (1.17–1.72)c 3.24 (2.46–4.26)c
  Unknown 62/320 (19.4%) 2.79 (2.06–3.78)c 1.77 (1.28–2.46)c
  negative 282/3557 (7.9%) referent referent
Site of tuberculosis
  extra-pulmonary TB 118/1255 (9.4%) 0.99 (0.80–1.22) ns
  Pulmonary TB 416/4371 (9.5%) referent
(Continued)International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Figure 3 Risk of TB death during the first month of TB treatment in different age groups in Chiang Rai, Thailand (2005–2008).
Table 2 (Continued)
Characteristics Patient died  
n/N (%)
Bivariate OR  
(95% CI)
Adjusted  
OR (95% CI)
Chest X-ray
  cavity 53/621 (8.5%) 0.90 (0.66–1.22) ns
  non-cavity 287/3040 (9.4%) referent
Patient type
  relapse 12/111 (10.8%) 1.11 (0.61–2.04) ns
  Failure 5/95 (5.3%) 0.51 (0.21–1.26)
  TAD 17/215 (7.9%) 0.79 (0.48–1.31)
  Other 17/287 (5.9%) 0.58 (0.35–0.95)c
  new 483/4918 (9.8%) referent
Sputum culture
  Growth 226/2540 (8.9%) 0.93 (0.71–1.22) ns
  no growth 80/844 (9.5%) referent
MDR TB
  Yes 4/46 (8.7%) 0.94 (0.33–2.65) ns
  no 197/2144 (9.2%) referent
Drug resistance
  One or moreb 33/393 (8.4%) 0.89 (0.6–1.31) ns
  none 168/1797 (9.3%) referent
Notes:a non-Thai means migrants from Lao and Myanmar; bresistance to at least one or more anti-TB drug: isoniazid, rifampicin, ethambutol, and streptomycin; cP , 0.05.
Data source: TB surveillance database collaboration between Chiang Rai Provincial Health Office, Thailand, and Research Institute of Tuberculosis, Japan.
Abbreviations: CI, confidence interval; MDR-TB, multidrug-resistant tuberculosis; NS, not significant; OR, odds ratio; TAD, treatment after default.
that considerably fuels the TB death rates. However, other 
WHO regions, such as Southeast Asia and Europe, currently 
have a different HIV prevalence and TB epidemiology from 
those of Sub-Saharan Africa.
Our observation in Northern Thailand has identified the 
first month of TB treatment as the time of highest risk for 
TB death. The same pattern has continued consecutively for 
more than a decade. Therefore, it would be practical to launch 
interventions focusing on the first month of TB treatment in 
order to cut mortality. Our finding is expected to be appli-
cable in many countries with similar TB epidemiology and 
problems globally.
Factors related to death in first  
month of TB treatment
Factors particularly associated with TB death in the first 
month of treatment were investigated to identify at-risk 
groups of patients. Clinical, laboratory, and sociodemo-International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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graphic factors were analyzed. We found that advancing age, 
HIV infection, and being Thai were strongly associated with 
death in the first month of TB treatment.
Previously, studies across the world have shown the fac-
tors associated with TB mortality. Mostly, factors associated 
with treatment outcome death were reported. A few studies 
pointed out the risk factors for early death. Even before the 
HIV pandemic, early TB death and an association with older 
patients were stated in England and Wales.11 A low body 
mass index less than 17.0 kg/m2 was also revealed as a risk 
factor for early mortality.12 A later study in Africa reported 
a higher death rate in HIV-positive TB patients.13
Our result has shown the higher risk of early TB death 
with advancing age. The death rate in the first month speci-
fied by age groups increased with advancing age (Table 1). 
AOR increased progressively with advancing age (Figure 3). 
TB patients aged above 65 years were found to have the 
  highest risk compared with other adult age groups (aOR 
17.71, 95% CI 8.54–36.73).
Previous studies in various regions of the world reported 
high risk for elderly TB patients, but the risk was not speci-
fied for death in the first month.7,11,14–19 Recently, analysis of 
TB surveillance data from 15 European Union (EU) countries 
during 2002–2004 reported that advancing age and resistance 
to isoniazid and rifampicin were the strongest risks of TB 
death.19 Therefore, our finding agreed with existing evidence 
for those at high-risk of TB death. Moreover, we specified 
the most likely time of death for these high-risk patients. 
However, the WHO definition of TB death covered death 
from any cause during TB treatment. Elderly TB patients 
might have comorbid diseases. Thus, it is difficult to claim 
TB as the sole contributor of death.
Currently, TB and HIV are two of the deadliest chronic 
infections globally.20 In our study cohort from 2005–2008, 
31% of all the TB patients were HIV positive. Among the 
deaths of patients during the first month, 35.6% were HIV 
positive (Table 1). HIV-infected TB patients have significant 
risk for death in the first month of TB treatment. The aOR 
was 3.24 (2.46–4.26). Unidentified status of HIV infection 
was also a risk factor for earlier TB death.
Previous studies have stated that HIV infection is an impor-
tant risk factor for TB mortality.21–23 Early deaths of TB–HIV 
co-infected patients were more likely caused by TB rather 
than other opportunistic infections.21 CD4 cell depletion is a 
possible explanation for the higher death rates in HIV-positive 
TB patients. Consequently, timely ART would be an important 
factor. Moreover, adverse effects are common because of inter-
action between antiretroviral drugs and anti-TB drugs.
Historically, TB was said to be a disease of poor people. 
The risk of TB death and its time of occurrence could be 
related to socioeconomic factors. However, in our analysis, 
occupation and educational status of the patients were not 
significant after adjustment with a multilogistic regression 
model. Final analysis showed that being a Thai citizen is a 
significant risk factor. A similar observation was reported in 
a European study and was explained as the healthy migrant 
effect.19 Bacteriological factors related to causal organism 
like culture positivity, drug resistance, and multidrug-
resistant TB (MDR-TB) were not significant factors in the 
current study. However, previous studies in Thailand and 
Europe reported that MDR-TB was a significant risk for 
overall TB death.7,19 The different finding could be due to a 
different time point of analysis and low level of MDR-TB 
prevalence in Chiang Rai.
More complete clinical data should be analyzed to 
  identify risk groups who could die earlier. Recently, a study of 
311 hospitalized TB patients in Brazil reported high   mortality 
rates among hospitalized TB patients in a highly HIV preva-
lent setting. Respiratory failure   requiring   mechanical ven-
tilation, smear negative sputum, and   consolidation in chest 
X-ray are identified as predictors of in-hospital death.24 It 
was a limitation of our study that we could not explore much 
about the factors related to anti-TB drugs, which were in fact 
a constant exposure in the study cohort. Most of our study 
cohort (more than 85%) comprised new cases treated by a 
WHO category I regimen8 (Table 1). Daphne and   colleagues 
have reported that the occurrence of serious side effects of 
anti-TB drugs were more common in patients aged over 
65 years and in HIV-positive patients.25 In the past, one of 
the inclusion criteria of clinical trials was patients’ age to be 
between 15 and 65 years.26 Therefore, it is hard to know about 
adverse events in TB patients aged above 65 years. Further 
studies of decades-old TB regimens in elderly patients would 
be necessary.
The time of highest TB deaths was found to be the earlier 
period in TB treatment. Delayed diagnosis and late presenta-
tion may be associated with early TB death. However, a study 
in Vietnam reported that diagnostic delay was not associated 
with TB treatment outcome mortality.18 Prospective studies 
beyond the scope of surveillance, based on contemporary 
evidence, should be assembled in future.
suggestions and proposed strategies
Our analysis showed that elderly patients and HIV co-
infected patients were the people at higher risk for early 
TB death. Elderly patients can have other allied illnesses, International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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such as malignancy, other respiratory infections, and 
underlying liver diseases, which may lead to earlier TB death. 
A   hospital-based prospective study focusing on the elderly 
and further analysis of more complete information on cause 
of death is necessary. A careful start to the administration 
of anti-TB drugs with a body weight-based adjusted dose, 
complete baseline clinical and laboratory investigations, and 
more frequent follow-ups are necessary. A TB hospital pro-
viding meticulous care of high-risk patients at the initiation 
of TB treatment in such an endemic area may be fruitful to 
save these risk groups.
To prevent early TB death in TB–HIV co-infected 
patients, ART coverage and access to ART is crucial in all 
settings, as the decline of overall death rate in later years of 
our observation has shown (Figure 1C). During the 12 years 
of the current study period, up to 2008, Thailand national 
guidelines recommended deferring ART in TB-HIV co-
infection until 2 months after initiation of TB treatment 
in cases with CD4 count more than 200 cells/ul.27,28 New 
national guidelines for Thailand in 2010 changed the rec-
ommendation to start ART earlier but still, to defer ART 
if CD4 count is above 350 cells/ul.29 Current international 
guidelines recommend starting ART in HIV infected persons 
with active TB disease irrespective of their CD4 count.30,31. 
This strategy would help to reduce the early TB deaths in 
TB-HIV patients.
In conclusion, current study findings are useful clues for 
launching realistic prevention strategies against TB deaths in 
many countries. Across the course of TB treatment, the first 
month sees the highest number of TB deaths. During that 
first month, elderly patients and HIV-infected patients are at 
significantly high risk of death. It is expected that prioritiz-
ing interventions focused on high-risk times and high-risk 
patients will diminish mortality related to TB globally.
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